Radiation Oncology

MD Anderson

Questions discussed in this category

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...

4 Answers available

Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?

If so, when and to what extent?

2 Answers available

How do you counsel your breast-cancer survivors about weight-loss/dietary modifications?

Do your recommendations differ if patients are pre or postmenopausal given the data?

3 Answers available

Papers discussed in this category

Journal of the National Cancer Institute, 2006-12-20

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study.

Medicine and science in sports and exercise, 2010-07

American College of Sports Medicine roundtable on exercise guidelines for cancer survivors.

J Clin Oncol, 2016 Feb 20

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.

Curr Breast Cancer Rep, 2016-01-01

Reducing the Risk of Breast Cancer Recurrence: an Evaluation of the Effects and Mechanisms of Diet and Exercise.

Crit Rev Food Sci Nutr, 2018 Apr 19

Meat, eggs, full-fat dairy, and nutritional boogeymen: Does the way in which animals are raised affect health differently in humans?

JAMA, 2018-02-20

Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial.

JAMA Oncol,

Prolonged Nightly Fasting and Breast Cancer Prognosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

BMC Cancer, 2019 Aug 19

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J Thorac Oncol, 2023 Feb 23

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.

J Clin Oncol, 2023 Jan 31

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Cancer journal (Sudbury, Mass.), 2020 Nov/Dec

Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 Feb 12

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

Journal for immunotherapy of cancer, 2021 Aug

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.

International journal of cancer, 2019 Feb 19

EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.

The Lancet. Respiratory medicine, 2023 May 05

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

N Engl J Med, 2022 Apr 11

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Radiation Oncology

MD Anderson

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology